The Florida Melanoma Trial I: A Prospective Multicenter Phase I/II Trial of Postoperative Hypofractionated Adjuvant Radiotherapy with Concurrent Interferon-Alfa-2b in the Treatment of Advanced Stage III Melanoma with Long-Term Toxicity Follow-Up

Table 9

Review of retrospective literature on combination of RT and IFN α-2b for melanoma.

Study	Site	Regimen	Radiation	Outcome
Hazard et al. [22]	melanoma 𝑛=10	concurrent or within 1 month	45–50 Gy	5/10 severe subacute/late complications including two patients with peripheral neuropathy, one patient with radiation necrosis in the brain, and two patients with radiation necrosis in the subcutaneous tissue.
Conill et al. [23]	melanoma 𝑛=18	concurrent or within 1 month	30 Gy/5 fractions (𝑛=8), 36 Gy/6 fractions (𝑛=8) 50 Gy/25 fractions (𝑛=2).	FFS at 3 years was 88%. All the patients experienced grade I acute skin reactions. Late toxicity was seen in one patient with grade III (RTOG) skin reaction and two with grade IV (RTOG) radiation-induced myelitis.
Gyorki et al. [24]	melanoma 𝑛=18	concurrent	40–50 Gy in 15–25 fractions	7/18 grade 3 skin reactions. Severe radiation-induced toxicity was seen in three patients, one who developed radiation pneumonitis, one who developed severe oral mucositis, and one who developed wound dehiscence.
Nguyen et al. [25]	melanoma 𝑛=3	concurrent	41.4–66 Gy	All three patients achieved local control at 24, 18 and 19 months followup; one patient developed widespread distant metastases.